Development of hepatotoxicity in HIV patients switching at least one protease inhibitor.
In order to evaluate the occurrence of hepatotoxicity in patients treated with antiretroviral therapy (ART) who switch protease inhibitor (PI), and the role of viral hepatitis in its development, we performed a retrospective study on 182 HIV patients treated with ART for 24 months. The presence of hepatitis viruses and alanine transaminase levels were evaluated. Hepatotoxicity developed in a low number of subjects without co-infection, but was significantly higher in co-infected patients (14/51 versus 62/131, P = 0.01). Ritonavir was associated with higher rates of severe hepatotoxicity in the co-infected group. Patients presenting any problems related to ART, including the development of hepatotoxicity, continued therapy by switching PI. The occurrence of hepatotoxicity with second/third choice PIs, including ritonavir, remained stable. Our results suggest that switching PI does not increase the occurrence of drug-related liver toxicity.
Aceti
Antonio
A
Department of Infectious Diseases, Sant'Andrea Hospital, II Faculty of Medicine, University of Rome La Sapienza, Rome, Italy. professoraceti@tiscali.it
Pasquazzi
Caterina
C
Zechini
Barbara
B
De Bac
Carlo
C
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D017320:HIV Protease Inhibitors; D000410:Alanine Transaminase